Effect of a dopamine D1/5 receptor antagonist on haloperidol-induced inhibition of the acquisition of conditioned fear

European Journal of Pharmacology

Volumn 519, Issue 3, 2005, Pages 253-258

  Inoue, Takeshi ^a   Izumi, Takeshi ^a   Xiao, Bai Li ^a   Kitaichi, Yuji ^a   Nakagawa, Shin ^a   Koyama, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anxiety; Conditioned fear; Dopamine D1 5 receptor; Dopamine D2 receptor

Indexed keywords

2 [[2 (DIMETHYLAMINO)ETHYL]THIO] 3 PHENYLQUINOLINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; LITHIUM CARBONATE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG RECEPTOR BINDING; ELECTRIC SHOCK; ELECTROSTIMULATION; FEAR; FREEZING; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TASK PERFORMANCE;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CONDITIONING (PSYCHOLOGY); DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEAR; HALOPERIDOL; LITHIUM CARBONATE; MALE; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D5; SEROTONIN ANTAGONISTS;

EID: 24644473005     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.08.003     Document Type: Article

References (20)

1. C.A. Altar, W.C. Boyar, A. Wasley, S.C. Gerhardt, J.M. Liebman, and P.L. Wood Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists Naunyn-Schmiedeberg's Arch. Pharmacol. 338 1988 162 168
2. American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia 1997 American Psychiatric Association Washington
3. M.M. Bernardi, F. De Souza, and J.P. Neto Effects of single and long-term haloperidol administration on open field behavior of rats Psychopharmacology 73 1981 171 175
4. F.P. Bymaster, D.O. Calligaro, J.F. Falcone, R.D. Marsh, N.A. Moore, N.C. Tye, P. Seeman, and D.T. Wong Radioreceptor binding profile of the atypical antipsychotic olanzapine Neuropsychopharmacology 14 1996 87 96
5. M.S. Fanselow Conditional and unconditional components of post-shock freezing Pavlovian J. Biol. Sci. 15 1980 177 182
6. D. Hoyer, D.E. Clarke, J.R. Fozard, P.R. Hartig, G.R. Martin, E.J. Mylecharane, P.R. Saxena, and P.P.A. Humphrey VII. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin) Pharmacol. Rev. 46 1994 157 203
7. T. Inoue, K. Tsuchiya, and T. Koyama Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear Pharmacol. Biochem. Behav. 55 1996 195 201
8. 1/5 antagonist SCH 23390 on the acquisition of conditioned fear Pharmacol. Biochem. Behav. 66 2000 573 578
9. P. Karlsson, L. Smith, L. Farde, C. Hänryd, G. Sedvall, and F.A. Wiesel Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients Psychopharmacology 121 1995 309 316
10. H. Kuribara, and S. Tadokoro Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses Pharmacol. Biochem. Behav. 14 1981 181 192
11. 2 receptors Psychopharmacology 112 1993 S40 S54
12. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo J. Pharmacol. Exp. Ther. 265 1993 498 508
13. H.Y. Meltzer Clinical studies of the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia Psychopharmacology 99 1992 S18 S27
14. H.Y. Meltzer, S. Matsubara, and J.-C. Lee Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values J. Pharmacol. Exp. Ther. 251 1989 238 246
15. D.N. Middlemiss, and M.D. Tricklebank Centrally active 5-HT receptor agonists and antagonists Neurosci. Biobehav. Rev. 16 1992 75 82
16. I. Muraki, T. Inoue, S. Hashimoto, T. Izumi, K. Ito, and T. Koyama Effect of subchronic lithium treatment on citalopram-induced increases in extracellular concentrations of serotonin in the medial prefrontal cortex J. Neurochem. 76 2001 490 497
17. G. Nowak, J. Arnt, and J. Hyttel EEDQ, a tool for ex vivo measurement of occupancy of D-1 and D-2 dopamine receptors Eur. J. Pharmacol. 153 1988 309 311
18. 2 antagonists modulates the effects of D-2 dopamine receptor blockade J. Pharmacol. Exp. Ther. 253 1990 1162 1170
19. 4 Neuropsychopharmacology 7 1992 261 284
20. K. Thomsen, and O.V. Olesen Long-term lithium administration to rats. Lithium and sodium dosage and administration, avoidance of intoxication, polyuric control rats Int. Pharmacopsychiatry 9 1974 118 124